Introduction
============

Access site complications occurred in 3.1--9.7% of patients who underwent neuroendovascular therapy.^[@B1]^ Retroperitoneal hematoma, in particular, may result in death due to massive bleeding. In recent years, hemostatic devices have been developed and improved with efficacy shown in many meta-analyses, but retroperitoneal hematoma still requires much caution.^[@B1]--[@B4]^ The Japanese Registry of Neuroendovascular Therapy (JR-NET) and JR-NET2 were retrospective registry studies of neuroendovascular therapy conducted by the Japanese Society for Neuroendovascular Therapy in Japan. JR-NET was conducted from January 2005 to December 2006, and JR-NET2 was conducted from January 2007 to December 2009. The registration parameters included disease-specific parameters and cross-sectional parameters common to all diseases. In this article, access site complications, a cross-sectional registration parameter in JR-NET and JR-NET2, are analyzed.

Materials and Methods
=====================

Of 11,114 patients in JR-NET and 20,854 patients in JR-NET2, a total of 31,836 evaluable patients with data on complications (JR-NET: 11,085, JR-NET2: 20,751) were included in the evaluation. Access site complications included hemorrhagic complications, ischemic complications, and infection. The hemostatic method, which was not described, was not assessed. The presence or absence of access site complication, age, sex, facility (main hospital or satellite hospital), timing of surgery (scheduledor emergency), investigator (supervisor, specialist, or non-specialist), treatment (cerebral aneurysm embolization, anteriovenous malformation embolization, spinal lesion, dural arteriovenous fistula, intracranial tumor, carotid artery stenting, extracranial percutaneous transluminal angioplasty \[PTA\], intracranial PTA, acute recanalization therapy, spasm treatment, or other), outcome of complication (asymptomatic, transiently symptomatic, moderately disabled, severely disabled, or dead), and effect of complication on the outcome of treatment (unrelated, possibly related, probably related, or related) were assessed.

Of patients who received treatment (cerebral aneurysm embolization, carotid artery stenting, extracranial PTA, and intracranial PTA) with a question about antiplatelet therapy as a registration parameter, 21,489 patients with available data were included in the assessment of preoperative use of antiplatelet drugs. In addition, a total of 22,234 patients who received treatment (cerebral aneurysm embolization and acute recanalization therapy) with a question about heparin as a registration parameter and who underwent carotid artery stenting, extracranial PTA, and intracranial PTA for which heparinization is generally recommended in the relevant guidelines and were thus assumed to have received heparin were included in the assessment of intraoperative heparinization.

These variables were analyzed using chi-square test for categorical variables and *t*-test for continuous variables, with a significance level of p \< 0.05. SPSS Ver.21 (IBM, Armonk, New York, USA) was used for statistical analysis.

Results
=======

Access site complications occurred in 195 (0.63%) of all 31,836 patients ([Table 1](#T1){ref-type="table"}). Significantly more of these complications resulted from surgery in main hospitals (186 patients, 0.67%, p \< 0.001) and scheduled surgery (167 patients, 0.73%, p \< 0.001). The incidence of complications was not different depending on the investigator\'s experience (nonspecialist, specialist, or supervisor).

By treatment, carotid artery stenting (81 patients, 1.04%, p \< 0.001), extracranial PTA (15 patients, 1.02%, p \< 0.001), and intracranial PTA (10 patients, 0.81%, p \< 0.05) were associated with a significantly higher incidence of complications, and tumor embolization (1 patient, 0.06%, p \< 0.05) was associated with a significantly lower incidence.

The outcome of treatment was asymptomatic or transiently symptomatic in 83.59%, permanently disabled in 18 patients (0.06%), and fatal in 2 patients (0.006%).

Use of antiplatelet drugs by treatment is shown in [Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}. Of patients who underwent aneurysm embolization, the majority used none (47.78%), and 25.16% and 22.39% used 1 and 2 drugs, respectively. On the other hand, approximately 10%, 68.2--78.2%, and 5.0--8.3% of patients who underwent carotid artery stenting, extracranial PTA, or intracranial PTA used 1, 2, and 3 drugs, respectively, with few receiving none (0.4--10.5%). The incidence of access site complications by use of antiplatelet drugs is shown in [Fig. 2](#F2){ref-type="fig"}. The incidence was significantly different among patients receiving none (21 patients, 0.34%), those receiving 1 or 2 drugs (122 patients, 0.84%), and those receiving 3 or more drugs (18 patients, 2.25%), with the highest incidence in those receiving 3 or more drugs.

The incidence of access site complications in the presence or absence of heparinization is shown in [Fig. 3](#F3){ref-type="fig"}. In all patients, the incidence was significantly different between heparinized patients (175 patients, 0.79%) and non-heparinized patients (3 patients, 0.22%) (p \< 0.05). In patients who underwent aneurysm embolization (p = 0.22) and acute recanalization therapy (p = 0.07), the incidence was not significantly different with or without heparinization. In heparinized patients, the incidence of access site complications was significantly higher in patients who underwent carotid artery stenting (81 patients, 1.08%, p \< 0.001) or extracranial PTA (13 patients, 1.03%, p \< 0.05) than in those who underwent aneurysm embolization (65 patients, 0.56%).

Discussion
==========

In this study, the incidence of access site complications was 0.63%, which is substantially lower than previously reported 3.1% to 9.7%.^[@B1],[@B2],[@B5]^ This may be in part because the puncture site vascular complication was not very clearly defined in the present study and there may have been unreported mild cases.

Scheduled surgery resulted in a higher incidence of access site complications than emergency surgery, although opposite results were reported in a study of cardiac catheterization using hemostatic devices.^[@B6]^ This may be because the number of patients who underwent scheduled surgery and emergency surgery was imbalanced, and carotid artery stenting, extracranial PTA, and intracranial PTA, which have a higher risk of puncture site vascular complications, were largely performed as scheduled surgery.

While there were no differences in experience among surgeons, no detailed assessment was made because data on which surgeons were actually involved in puncture or hemostasis were not available.

By treatment, carotid artery stenting, extracranial PTA, and intracranial PTA were associated with higher incidence of complications. This may be partly explained by intraoperative heparinization and preoperative use of multiple antiplatelet drugs. It may also be accounted for frequent use of tools with a wide diameter such as sheath size.

The outcome of treatment was asymptomatic or transiently symptomatic in 83.5%, but disabled in 9.2%. Death-related access site complications occurred in 2 patients (0.006%), but these patients had not only access site complications, but also other complications (ischemic and hemorrhagic complications). The outcome of treatment was not related to access site complications in half of the cases and was related only in the remaining half. In this study, whether the outcome of treatment was affected by access site complications cannot be definitively concluded, because some patients had not only access site complications, but also other complications.

As for the limitations of the study, it was a retrospective registry study, and there were many patients with incomplete data entry. A low incidence of access site complications in satellite hospitals might have reflected incomplete data entry. In addition, the dose of heparin was not described, but statistical analysis was performed on the assumption that heparin was used in patients who underwent angioplasty, possibly generating a bias. The hemostatic method was also not described.

Conclusion
==========

The incidence of puncture site vascular complications was 0.63%. These complications resulted in permanent disability in 18 patients (0.06%) and death in 2 patients (0.006%). Carotid artery stenting, extracranial PTA, intracranial PTA, heparinization, and use of antiplatelet drugs were associated with higher incidence of complications. In particular, use of multiple antiplatelet drugs was associated with an increased risk, requiring caution.
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###### 

Charactaristics of puncture site vascular compilications

                                      Total                    Puncture site complication (%)   \% in access site complication   Data unavailable   P value
  ----------------------------------- ------------------------ -------------------------------- -------------------------------- ------------------ ----------
    Case                              31,836                                                                                                        
    Age (± SD)                        63.73 ± 13.81 (0--104)                                                                                        
    All complication                  2,640 (8.29)             195 (0.63)                                                                           
  Background                                                                                                                                        
    Age ± SD (range)                  69.22 ± 11.35 (15--89)                                                                                        NS
    Male                              16,944                   94 (0.55)                        48.21                                               NS
  Facility                                                                                                                       1                  \< 0.001
    Main hospital                     27,794                   186 (0.67)                       95.38                                               
    Satellite                         4,019                    8 (0.20)                         4.10                                                
  Operation time                                                                                                                 0                  \< 0.001
    Schedule                          22,743                   167 (0.73)                       85.64                                               
    Emergency                         9,037                    28 (0.31)                        14.36                                               
  Operator                                                                                                                       0                  NS
    Supervisor                        16,705                   95 (0.57)                        48.22                                               
    Specialst                         12,686                   80 (0.63)                        40.61                                               
    Non-specoalist                    2,366                    20 (0.85)                        10.15                                               
  Treatment                                                                                                                      0                  \< 0.001
    Cerebaral aneurysm embolization   13,019                   67 (0.51)                        34.36                                               NS
    Arterio-venous malformation       986                      1 (0.10)                         0.51                                                NS
    Spinal lesion                     196                      0                                0.00                                                NS
    Dural AVF                         2,230                    5 (0.22)                         2.56                                                NS
    Tumor                             1,736                    1 (0.06)                         0.51                                                \< 0.05
    Carotid artery stent              7,818                    81 (1.04)                        41.54                                               \< 0.001
    Entercranial PTA                  1,476                    15 (1.02)                        7.69                                                \< 0.001
    Intracranial PTA                  1,235                    10 (0.81)                        5.13                                                \< 0.05
    Acute recanalization therapy      1,410                    9 (0.64)                         4.62                                                NS
    Spasm treatment                   645                      1 (0.16)                         0.51                                                NS
    Others                            1,085                    5 (0.22)                         2.56                                                NS
  Outcome                                                                                                                        12                 
    Asymptomatic                                               84                               43.08                                               
    Traniently symptomatic                                     79                               40.51                                               
    Modrate disabled                                           11                               5.64                                                
    Sever disabled                                             7                                3.59                                                
    Dead                                                       2                                1.03                                                
  Influence of complication                                                                                                      12                 
    Unrelated                                                  92                               47.18                                               
    Possible related                                           3                                1.54                                                
    Probable related                                           0                                0.00                                                
    Related                                                    88                               45.13                                               

AVF: arteriovenous fistula, NS: not significant, PTA: percutaneous transluminal angioplasty, SD: standard deviation.

###### 

Use of antiplatelet drugs by treatment

                                     0              1 drug      2 drugs        More than 3 drugs                                           
  ---------------------------------- -------------- ----------- -------------- ------------------- --------------- ----------- ----------- -----------
  Total (n = 21,489)                 6,131 (28.5)   21 (0.34)   4,449 (20.7)   36 (0.81)           10,110 (47.0)   86 (0.85)   799 (3.7)   18 (2.25)
  Aneurysm (n = 11,872)              5,932 (50.0)   19 (0.32)   3,124 (26.3)   22 (0.70)           2,780 (23.4)    21 (0.76)   36 (0.3)    1 (2.79)
  Carotid artery stent (n = 7,259)   31 (0.4)       1 (3.2)     949 (13.1)     9 (0.95)            5,677 (78.2)    54 (0.95)   602 (8.3)   14 (2.32)
  Extracranial PTA (n = 1,232)       49 (4.3)       0           236 (20.9)     3 (1.27)            885 (78.2)      7 (0.79)    62 (5.5)    2 (3.23)
  Intracranial PTA (n = 1,126)       119 (10.6)     1 (0.84)    140 (12.4)     2 (1.42)            768 (68.2)      4 (0.52)    99 (8.8)    1 (1.01)

PTA: percutaneous transluminal angioplasty.
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